Stock CYTO ALTAMIRA THERAPEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Altamira Therapeutics Ltd.

Equities

CYTO

BMG0360L1349

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-05-06 pm EDT 		5-day change 1st Jan Change
1.58 USD -4.24% Intraday chart for Altamira Therapeutics Ltd. +0.64% -54.60%
May. 01 Altamira Therapeutics Ltd. Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation CI
Apr. 24 Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal CI

Valuation

Fiscal Period: December 2019 2023 2024 2025 2026
Capitalization 1 5.174 1.164 3.21 - -
Enterprise Value (EV) 1 3.789 1.164 3.21 3.21 3.21
P/E ratio -0.69 x -0.37 x - - -
Yield - - - - -
Capitalization / Revenue - - - - -
EV / Revenue - - - - -
EV / EBITDA -715,778 x - - - -
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book - - - - -
Nbr of stocks (in thousands) 8.26 398 2,240 - -
Reference price 2 626.7 2.927 1.433 1.433 1.433
Announcement Date 4/16/20 4/10/24 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2023 2024 2025 2026
Net sales 1 - - - - -
EBITDA -7.228 - - - -
EBIT 1 -7.259 - -7.846 -10.29 -12.76
Operating Margin - - - - -
Earnings before Tax (EBT) -6.826 - - - -
Net income -6.632 -3.869 - - -
Net margin - - - - -
EPS -912.0 -7.880 - - -
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 4/16/20 4/10/24 - - -
1CHF in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 1 - - - - -
EBITDA - - - - -
EBIT -3.152 - - - -
Operating Margin - - - - -
Earnings before Tax (EBT) - - - - -
Net income -3.028 - - - -
Net margin - - - - -
EPS -248.0 - - - -
Dividend per Share - - - - -
Announcement Date 4/16/20 - - - -
1CHF in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position 1.38 - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - - - - -
ROA (Net income/ Total Assets) - - - - -
Assets - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex 3.02 - - - -
Capex / Sales - - - - -
Announcement Date 4/16/20 4/10/24 - - -
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ALTAMIRA THERAPEUTICS LTD. Stock Altamira Therapeutics Ltd.
-54.60% 3.7M
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.44% 106B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+0.82% 104B
ARGENX SE Stock argenx SE
+6.72% 23.25B
BIONTECH SE Stock BioNTech SE
-13.89% 22.5B
GENMAB A/S Stock Genmab A/S
-6.64% 18.7B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.26% 17.95B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.98% 16.99B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+8.67% 14.26B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+41.08% 12.76B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CYTO Stock
  4. Financials Altamira Therapeutics Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW